The company’s hepatitis B virus (HBV) program remains at a critical juncture following Phase 2b study results. Data from the ENRICH and ENHANCE trials highlight the role of BRII-179 in potentially improving functional cure rates, though the firm has paused Phase 3 development of elebsiran due to an ongoing arbitration with Vir Biotechnology. Management noted that a recent product recall involving testing kits used in the ENHANCE study is currently under assessment, with preliminary indicators suggesting minimal impact on the overall interpretation of trial outcomes.
Beyond infectious diseases, Brii Bio has transitioned its discovery efforts toward oncology. In August, the company dosed the first participant in a clinical study for BRII-5395, an mRNA therapeutic vaccine targeting advanced hepatocellular carcinoma. CEO Dr. Zhi Hong emphasized that this move reflects the company’s ability to translate internal research into clinical assets. Financially, the firm reported a disciplined reduction in expenses, with research and development costs falling 16% to 98.3 million RMB compared to the same period in 2025, ensuring operational liquidity through 2029.
Comments (0)
No comments yet. Be the first!